Vaxinz

What Vaxinz does

Vaxinz is a pre-commercial biotechnology company founded in 2020 that develops vaccines using a proprietary second-generation non-replicative adenoviral vector platform. The platform is based on replication-deficient human adenovirus 5 (Ad5) with ΔE1 and ΔE3 deletions and incorporates capsid protein engineering (Fiber, Hexon, Penton) to optimize tissue targeting and immunogen expression. The company's stated design objectives are single-shot administration, balanced TH1/TH2 immune responses, enhanced immunodominance through meticulous immunogen selection, and reduced side effects via lower dosing.

The lead product candidate is CoroVaxG.3.D-FR, a polyvalent second-generation SARS-CoV-2 vaccine designed to cover variants of concern including Gamma, Delta, and Omicron. The pipeline extends to inhalatory adenoviral vaccine candidates for respiratory viruses (SARS-CoV-2, Influenza), an intramuscular Yellow Fever Virus vaccine, and an intramuscular Chikungunya Virus vaccine. Supporting the pipeline is a Rational and AI-Assisted Immunogen Design Platform that uses AlphaFold and RoseTTAFold for structural prediction combined with molecular dynamics simulations and quantum mechanics evaluation, alongside a proprietary Pseudoviral Platform for efficacy testing and small-scale upstream/downstream production capability. Vaxinz has published its COVID vaccine research in Vaccines (Basel) in 2021 and NPJ Vaccines in 2023.

Vaxinz generates no commercial revenue and all candidates remain in research or pre-clinical development. The company targets Southern Hemisphere populations in Latin America and Sub-Saharan Africa facing disproportionate burdens from mosquito-borne and respiratory diseases, with secondary applicability to global health organizations focused on pandemic preparedness. Strategic research partnerships underpin operations, including the founding alliance with Argentina's Leloir Institute and CONICET for SARS-CoV-2 vaccine co-development, clinical research with Hospital Italiano de Buenos Aires, preclinical research with Centro de Medicina Comparada, and a collaboration with Securitas Bio. The company operates with 1-10 employees across US (Commerce) and Brazil (São Paulo).

Name

Vaxinz

Legal name

Vaxinz Inc.

Website

https://vaxinz.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Vaxinz is a pre-commercial biotechnology company developing single-shot adenoviral vector vaccines for respiratory and mosquito-borne diseases prevalent in the Southern Hemisphere, using AI-assisted immunogen design and proprietary pseudoviral testing.

Ownership category

akta.pro rank

Product category

Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD), Travel & Tropical Disease Vaccines (HLAIAEAE), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Adenoviral vector vaccines
• Second-generation vaccines
• Infectious disease vaccines
• AI-assisted immunogen design
• Mosquito-borne disease vaccines

Headquarters

HQ city

Commerce

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Marketing channels3 records

Core offering

Vaxinz develops proprietary vaccine candidates built on a second-generation non-replicative adenoviral vector platform (Adenovirus 5 with ΔE1 and ΔE3 deletions) combined with AI-assisted immunogen design. Its lead candidate CoroVaxG.3.D-FR targets SARS-CoV-2 variants of concern, with additional pipeline candidates for Yellow Fever Virus, Chikungunya Virus, and inhalatory respiratory virus vaccines. The company is pre-commercial and focused on vaccine research and development for diseases prevalent in the Southern Hemisphere.

Product overview

Vaxinz offers a proprietary second-generation non-replicative adenoviral vector vaccine platform (based on Adenovirus 5 with ΔE1 and ΔE3 deletions) that enables development of single-shot, long-lasting vaccines with balanced TH1/TH2 immune responses. The platform includes AI-assisted immunogen design capabilities using AlphaFold and RoseTTAFold, molecular dynamics simulations, and a pseudoviral efficacy testing platform. The lead product is CoroVaxG.3.D-FR, a second-generation SARS-CoV-2 vaccine targeting variants of concern. The pipeline encompasses inhalatory vaccines for respiratory viruses (SARS-CoV-2, Influenza), intramuscular vaccines for mosquito-borne diseases (Yellow Fever Virus, Chikungunya Virus), and a versatile platform designed for rapid response to future pandemics.

Differentiator

Problem solved

Functional benefit

Products and services

• CoroVaxG.3.D-FR Second-generation SARS-CoV-2 vaccine and Vaxinz's lead candidate, designed as an intramuscular polyvalent vaccine to provide robust and long-lasting immune protection against prevalent variants including Gamma, Delta, Omicron, and other variants of concern. Targeted at governments, public health agencies, and global health organizations.
• Inhalatory Vaccines for Respiratory Viruses Novel vaccine candidates leveraging adenoviral vector technology for inhalation delivery, targeting respiratory viruses including SARS-CoV-2 and Influenza, designed to take advantage of adenoviral vectors' properties for respiratory delivery. Aimed at populations in the Southern Hemisphere and global respiratory virus prevention.
• Yellow Fever Virus (YFV) Vaccine Intramuscularly administered vaccine targeting Yellow Fever Virus, developed to mitigate the impact of mosquito-borne diseases in the Southern Hemisphere. Targeted at populations in Latin America and Sub-Saharan Africa facing endemic Yellow Fever risk.
• Chikungunya Virus (CHKV) Vaccine Intramuscularly administered vaccine targeting Chikungunya Virus, developed to address mosquito-borne disease burden in the Southern Hemisphere. Targeted at populations in Latin America and Sub-Saharan Africa facing endemic Chikungunya risk.
• Second-Generation Non-Replicative Adenoviral Vector Platform Proprietary vaccine technology platform based on replication-deficient human adenoviral vectors (Adenovirus 5 with ΔE1 and ΔE3 deletions), engineered for enhanced immunogenicity, heightened safety, and compatibility with diverse immunogens. Includes capsid protein engineering (Fiber, Hexon, Penton) and optimized immunogen expression cassettes. Designed for licensing and co-development with research institutions and pharmaceutical partners.
• Rational and AI-Assisted Immunogen Design Platform Vaccine immunogen design technology combining in-depth literature analysis, cutting-edge AI tools (AlphaFold, RoseTTAFold), molecular dynamics simulations, and quantum mechanics evaluation for accelerated and optimized immunogen development. Used internally and as part of Vaxinz's co-development partnerships.
• Pseudoviral Platform Sophisticated testing platform developed for evaluating vaccine efficacy, enabling rigorous testing of novel vaccine candidates and characterization of immunogenic responses including the nature and duration of immune response. Used internally for Vaxinz's vaccine development programs.
• Small-Scale Upstream and Downstream Development Small-scale production setup for upstream and downstream vaccine development processes, designed for scalable and transferable production suitable for industrial-scale manufacturing. Supports Vaxinz's vaccine pipeline development and future manufacturing scale-up.

Quantifiable outcome

• Publication in Vaccines (Basel) 2021: Single dose of hybrid hAdV5-based anti-COVID-19 vaccine induces long-lasting immune response and broad coverage against VOC
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Instituto Leloir (Leloir Institute)coreStrategic or Co-development PartnerResearch partnership for vaccine development. The Leloir Institute, a leading Argentine research institution in biochemistry and molecular biology, collaborates with Vaxinz on adenoviral vector-based vaccine research and development. This partnership was formalized through an agreement signed with CONICET for the development of second-generation SARS-CoV-2 vaccines.
• CONICET (National Scientific and Technical Research Council)coreStrategic or Co-development PartnerFormal research agreement signed between Vaxinz, Leloir Institute, and CONICET for the development of second-generation vaccines against SARS-CoV-2. CONICET is Argentina's principal government agency supporting scientific research, providing institutional framework and research infrastructure for vaccine development collaboration.
• Hospital Italiano de Buenos AirescoreStrategic or Co-development PartnerClinical research partnership with Hospital Italiano, a major Argentine medical institution. The hospital serves as a clinical research partner providing access to clinical trial capabilities and medical expertise for vaccine development.
• Centro de Medicina Comparada (CMC)coreStrategic or Co-development PartnerPartnership with Centro de Medicina Comparada for preclinical research capabilities. CMC provides comparative medicine expertise essential for vaccine efficacy and safety testing in appropriate animal models.

Recent moves6 records

Expansion highlights5 records

Emerging players

• Gritstone bio: Gritstone uses adenoviral and self-amplifying mRNA vector platforms for infectious disease and oncology vaccines, with comparable AI-informed antigen design and a similarly pre-commercial/early clinical stage profile.
• Codagenix: Clinical-stage synthetic biology vaccine developer targeting respiratory and tropical diseases with platform-based approaches, comparable in stage, size, and global health disease focus to Vaxinz.
• Vaxart: Vaxart develops oral adenoviral vector-based vaccines for respiratory and enteric diseases, including influenza and COVID-19, sharing Vaxinz's adenoviral-vector DNA but with a distinct oral delivery approach.
• Brii Biosciences: Clinical-stage biotech focused on infectious diseases including COVID-19 with partnerships across China and emerging markets, sharing Vaxinz's emerging-market-focused vaccine development thesis.

Regional players

• Bharat Biotech: Indian vaccine manufacturer with a broad pipeline including viral vector and inactivated platforms serving tropical disease and emerging market populations, comparable to Vaxinz in targeting Southern Hemisphere infectious disease burden.
• Bio-Manguinhos/Fiocruz: Brazilian public-sector vaccine manufacturer producing Yellow Fever and other endemic disease vaccines for Brazil and Latin America, representing both a potential partner and competitor for Vaxinz's Southern Hemisphere strategy.

Broad incumbents

• Janssen (Johnson & Johnson): Janssen's Ad26-based Ebola and COVID-19 vaccines are the most prominent adenoviral vector vaccine franchises globally, providing the incumbent benchmark for vector technology, manufacturing scale, and regulatory pathways that Vaxinz's Ad5 platform competes against.
• Gamaleya Research Institute: Developed the Sputnik V and Sputnik Light Ad5/Ad26 vector COVID-19 vaccines, representing another major adenoviral vector vaccine program targeting similar global health and emerging market segments.

Direct peers

• GeoVax Labs: GeoVax uses MVA viral vector and other platforms for vaccines against emerging infectious diseases and immuno-oncology, with a comparable profile of a small clinical-stage biotech developing platform-based vaccines for global health indications.
• CanSino Biologics: CanSino developed Convidecia, an Ad5-based COVID-19 vaccine, making it the most direct comparator on adenoviral vector technology for infectious disease vaccines targeting both pandemic preparedness and emerging market populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vaxinz-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxinz